Hepatitis B Virus News and Research

RSS

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

Leading medical experts from throughout the UK will be gathering in Edinburgh today and tomorrow (21-22 April 2004) to arrive at a consensus on how best to treat and manage the 'silent epidemic' of hepatitis C - a virus which is estimated to be carried by over 400,000 people in the UK and which continues to spread globally, as the majority of carriers do not realise they have been infected.

21 Jun 2005

Researchers discover how hepatic-C virus evades immune system in acute and chronic infections

Researchers at Johns Hopkins have uncovered how a majority of the genetic changes in the hepatic-C virus, the most common cause of liver disease, allow it to evade the body's immune system during infection.

10 Jun 2005

Scientists produce for the first time an infectious form of the hepatitis C virus in laboratory cultures of human cells

The finding, reported in the June 9 issue of Science Express, will allow scientists to study every stage of the HCV life cycle and develop drugs to treat this life-threatening disease that affects more than 170 million people around the world.

9 Jun 2005

Tobacco use persists after liver transplant for alcoholic liver disease

Alcohol and tobacco often go hand-in-hand. Studies have shown that approximately 90 percent of problem drinkers also smoke or chew tobacco. But tobacco use is not adequately addressed when patients undergo liver transplantation due to alcoholic liver disease, say authors of a new report.

26 May 2005

Study shows using expanded critera donors is safe

Patients who had received livers from hepatitis B virus core antibody (HBcAb) positive (indicates prior exposure to hepatitis B) and/or hepatitis C virus (HCV) positive donors had similar graft and patient survival compared to patients who received HBcAb negative or HCV negative livers, according to a study by the University of Pittsburgh's Thomas E. Starzl Transplantation Institute.

25 May 2005

Benitec announces clinical candidate for the treatment of Hepatitis C

Benitec Ltd. announced today that it has identified a highly promising clinical candidate for its RNA interference (RNAi)-based therapeutic against the hepatitis C virus (HCV).

10 May 2005

BMA calls for mass child vaccinations for hepatitis B virus (HBV)

The British Medical Association (BMA) has today called for all children in the UK to be immunised against a potentially fatal liver disease caused by the hepatitis B virus (HBV).

9 May 2005

Small number of genes can predict response to chronic hepatitis C therapy

For the first time, physicians at University Health Network and University of Toronto have identified a small subset of genes that can predict whether a patient with chronic Hepatitis C will be able to respond to current treatments.

2 May 2005

New drug to treat chronic hepatitis B

The U.S. Food and Drug Administration (FDA) has given approval for a new drug to treat the potentially life-threatening disease Chronic hepatitis B.

30 Mar 2005

Patients with Hepatitis C have a significant decrease in their health-related quality-of-life

Patients with Hepatitis C virus (HCV) have a significant decrease in their health-related quality-of-life (HRQOL), although treatment success can mitigate this negative effect.

28 Mar 2005

Key target for Foot-and-Mouth drug revealed

A complete picture of Foot-and-Mouth Disease's key replication enzyme could lead to the development of new drugs to control the disease without recourse to vaccination or slaughter, scientists report today.

21 Mar 2005

New HIV screening method, nucleic acid amplification testing (NAAT)

Adding a new HIV screening method, called nucleic acid amplification testing (NAAT), to standard HIV testing, researchers were able to uncover six percent more cases of HIV infection in urban STD and drug treatment clinics and HIV testing sites in Atlanta than with standard HIV antibody tests alone.

27 Feb 2005

Pfizer acquires Idun Pharmaceuticals

Pfizer today announced that it has entered into an agreement to acquire Idun Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis, a process of cell death that occurs in a broad range of diseases.

24 Feb 2005

Association noted between certain non-lver cancers and hepatitis C

People infected with the hepatitis C virus (HCV) have a higher risk of developing non-Hodgkin's lymphoma and multiple myeloma, according to a recent study of the Swedish population.

22 Feb 2005

Scientists have replicated hepatitis C virus (HCV) in the laboratory

For the first time, scientists have replicated hepatitis C virus (HCV) in the laboratory. The ability to replicate HCV in cell culture will allow researchers to better study the life cycle and biology of this virus and to test potential antiviral compounds, which may lead to new therapies for the liver disease that results from infection with HCV.

22 Feb 2005

Studies reveal methods viruses use to sidestep immune system

A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.

17 Feb 2005

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B Virus (HBV), an acute sometimes fatal form of viral hepatitis caused by a DNA virus that persists in the blood serum and is transmitted by sexual contact or by transfusion or by ingestion of contaminated blood or other bodily fluids.

14 Feb 2005